Literature DB >> 8491678

Carcinoma of the prostate: results of radical radiotherapy (1970-1985).

W Duncan1, P Warde, C N Catton, A J Munro, R Lakier, T Gadalla, M K Gospodarowicz.   

Abstract

PURPOSE: To determine the outcome and prognostic factors in patients with localized carcinoma of the prostate treated with external beam radiation therapy. METHODS AND MATERIALS: A retrospective review of 999 patients with histologically confirmed adenocarcinoma of the prostate treated radically with megavoltage irradiation at the Princess Margaret Hospital between 1970 and 1985. Prognostic factors were analyzed using recursive partitioning method.
RESULTS: Overall survival at 5 and 10 years were 69.8% and 40.1% for the whole group. The cause-specific survival rates were 78.9% and 53.5%, respectively. The cause-specific survival rates were significantly different at 10 years by T stage, T1 being 79.0%, T2 66.0%, T3 55% and T4 22%. The overall clinical local control rates was 77% in the first 5 years following treatment. There was no statistically significant difference in the local control rates of T1 and T2 stage disease at 5 years, the combined rate being 88%. Significant differences were observed between other stages, being 76% for T3 and 55% for T4. At 10 years the control rate for T1 tumours was maintained for T1 stage disease (92%) but was significantly reduced for other stages, T2 75%, T3 67% and for T4 37%. In the whole group 33.5% of patients had distant metastases in the first 5 years. The distant relapse rates at 10 years were significantly different by T stage, being 20% for T1, 33% for T2, 55% for T3 and 87% for T4. Multivariate analysis demonstrated that only T stage and histological grade were independent prognostic covariates for cause-specific survival. Age was the only other independent variate in terms of overall survival. The late radiation related morbidity was 2.3% overall; 1.3% affecting rectum and recto-sigmoid and 1.0% arising in the bladder.
CONCLUSION: In terms of survival the results of radiotherapy of intracapsular disease were excellent, but they were less satisfactory in patients with direct extracapsular extension. The assessment of local control was difficult and may have reflected more the lack of local disease progression rather than true local tumor control. The treatment was well tolerated and there were few serious late complications.

Entities:  

Mesh:

Year:  1993        PMID: 8491678     DOI: 10.1016/0360-3016(93)90198-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

Review 1.  Prostate cancer: 2. Natural history.

Authors:  R K Nam; M A Jewett; M D Krahn
Journal:  CMAJ       Date:  1998-09-22       Impact factor: 8.262

Review 2.  Prostate cancer: 7. Radiation therapy for localized disease.

Authors:  P Warde; C Catton; M K Gospodarowicz
Journal:  CMAJ       Date:  1998-12-01       Impact factor: 8.262

Review 3.  Prostate cancer.

Authors:  D Mazhar; J Waxman
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

4.  Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial.

Authors:  Alan Pollack; Alexandra L Hanlon; Eric M Horwitz; Steven J Feigenberg; Andre A Konski; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; C-M Charlie Ma; Shawn W McNeeley; Mark K Buyyounouski; Robert A Price
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-19       Impact factor: 7.038

Review 5.  Systematic review of hypofractionated radiation therapy for prostate cancer.

Authors:  Nicholas G Zaorsky; Nitin Ohri; Timothy N Showalter; Adam P Dicker; Robert B Den
Journal:  Cancer Treat Rev       Date:  2013-03-01       Impact factor: 12.111

6.  Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer.

Authors:  Mark Ritter
Journal:  Semin Radiat Oncol       Date:  2008-10       Impact factor: 5.934

7.  Hypofractionation for prostate cancer.

Authors:  Mark Ritter; Jeffrey Forman; Patrick Kupelian; Colleen Lawton; Daniel Petereit
Journal:  Cancer J       Date:  2009 Jan-Feb       Impact factor: 3.360

8.  Review of hypofractionated radiotherapy for prostate cancer.

Authors:  Despina Spyropoulou; Dimitrios Kardamakis
Journal:  ISRN Oncol       Date:  2012-08-13

9.  Hypofractionated external-beam radiation therapy (HEBRT) versus conventional external-beam radiation (CEBRT) in patients with localized prostate cancer: a systematic review and meta-analysis.

Authors:  Tobias Engel Ayer Botrel; Otávio Clark; Antônio Carlos Lima Pompeo; Francisco Flávio Horta Bretas; Marcus Vinicius Sadi; Ubirajara Ferreira; Rodolfo Borges Dos Reis
Journal:  Core Evid       Date:  2013-03-07

Review 10.  Radiotherapy for t3 prostate cancer.

Authors:  Andrew Bayley; Mary K Gospodarowicz
Journal:  Curr Urol Rep       Date:  2003-06       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.